嚢胞性線維症（CF）肺疾患の世界市場（2024年版）：薬剤タイプ別（CFTR調節薬、気管支拡張薬、粘液溶解薬、抗感染薬）、投与経路別、流通経路別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

Global Cystic Fibrosis (CF) Lung Disease Market (2024 Edition): Analysis By Drug Type (CFTR Modulators, Bronchodilators, Mucolytics, Anti-infectives), Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリーこの調査レポートは世界の嚢胞性線維症肺疾患市場を薬剤タイプ別（CFTR調節薬、気管支拡張薬、抗感染薬）、投与経路別（経口、吸入、静脈内）、流通チャネル別（病院薬局、小売薬局... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2024年1月1日	US$2,450 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	250	英語

サマリー

エグゼクティブ・サマリー

この調査レポートは世界の嚢胞性線維症肺疾患市場を薬剤タイプ別（CFTR調節薬、気管支拡張薬、抗感染薬）、投与経路別（経口、吸入、静脈内）、流通チャネル別（病院薬局、小売薬局、オンラインチャネル）に詳細に分析しています、薬剤タイプ別（CFTR調節薬、気管支拡張薬、抗感染薬）、投与経路別（経口、吸入、静脈内）、流通チャネル別（病院薬局、小売薬局、オンラインチャネル）の市場セグメントを、2019-2022年の過去期間、2023年の予測期間、2024-2029年の予測期間について掲載しています。

調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、ドイツ、英国、フランス、イタリア、スペイン、中国、オーストラリア、インド）の詳細な分析をカバーしています。さらに、市場規模、年間成長＆潜在力分析、市場プレイヤーの競合調査、投資機会、需要予測などのデータも提示しています。

また、市場成長指標、阻害要因、需給リスク、その他の重要統計、市場の進化に関連する現在および将来の市場動向の完全評価も行っています。予測期間2024-2029年において、嚢胞性線維症肺疾患の世界市場はCAGR 25.7%で成長すると予測されます。嚢胞性線維症肺疾患の世界市場は、2022年の107億5,000万米ドルから2029年末までに468億7,000万米ドルを創出すると予測されます。

嚢胞性線維症肺疾患市場は、治療介入の継続的な進歩によって推進されている。製薬会社は革新的な治療法を最前線に送り出すため、研究開発に多額の投資を行っている。さらに、遺伝子治療やCFTRモジュレーターのような新規薬剤や治療法の出現は、嚢胞性線維症患者の治療状況を大幅に改善した。これらの進歩は患者の予後を改善するだけでなく、市場全体の成長にも貢献している。

さらに、医療従事者や患者の間で嚢胞性線維症に対する認識が高まっていることも、市場成長の重要なドライバーとなっている。診断能力の向上と疾患教育への取り組みの強化は、早期発見と早期介入に貢献し、市場成長に寄与している。

レポートの範囲

- 本レポートでは、嚢胞性線維症肺疾患市場を金額（10億米ドル）別に分析しています。

- 本レポートでは、嚢胞性線維症肺疾患市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介します。

- 嚢胞性線維症肺疾患市場を薬剤タイプ別（CFTR調節薬、気管支拡張薬、粘液溶解薬）に分析しています。

- 嚢胞性線維症肺疾患市場を投与経路別（経口、吸入、静脈内）に分析した報告書

- 嚢胞性線維症肺疾患市場を流通チャネル別（病院薬局、小売薬局、オンラインチャネル）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、薬剤タイプ別、投与経路別、流通チャネル別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、嚢胞性線維症肺疾患治療薬のパイプラインフレームワークも分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発を追跡しています。本レポートで分析対象とした企業は、Vertex Pharmaceuticals、Gsk plc、Novartis AG、Roche Holding AG、Bayer AG、Gilead Sciences、Chiesi Farmaceutici S.p.A.、Enterprise Therapeutics、Laurent Pharmaなどです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Cystic Fibrosis Lung Disease Market: Historic and Forecast (2019-2029)

3.1 Cystic Fibrosis Lung Disease: Fact Sheet

3.2 Cystic fibrosis therapies targeting Lung symptoms in Pipeline

3.3 Cystic fibrosis small molecule therapies and their targeted mutations

3.4 Non-viral vectors commonly used for gene and drug delivery in CF patients

3.5 Global Cystic Fibrosis Lung Disease Market: Dashboard

3.6 Global Cystic Fibrosis Lung Disease Market: Market Value Assessment, 2019H-2029F (USD Billion)

3.7 Impact of COVID-19 on Global Cystic Fibrosis Lung Disease Market

3.8 Global Cystic Fibrosis Lung Disease Market Segmentation: By Drug Type

3.8.1 Global Cystic Fibrosis Lung Disease Market, By Drug Type Type Overview

3.8.2 Global Cystic Fibrosis Lung Disease Market Size, By CFTR modulators, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.3 Global Cystic Fibrosis Lung Disease Market Size, By Bronchodilators, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.4 Global Cystic Fibrosis Lung Disease Market Size, By Mucolytics, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.5 Global Cystic Fibrosis Lung Disease Market Size, By Anti infectives, By Value, 2019H-2029F (USD Billion & CAGR)

3.9 Global Cystic Fibrosis Lung Disease Market Segmentation: By Route of Administration

3.9.1 Global Cystic Fibrosis Lung Disease Market, By Route of Administration Overview

3.9.2 Global Cystic Fibrosis Lung Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.3 Global Cystic Fibrosis Lung Disease Market Size, By Inhalation, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.4 Global Cystic Fibrosis Lung Disease Market Size, By Intravenous, By Value, 2019H-2029F (USD Billion & CAGR)

3.10 Global Cystic Fibrosis Lung Disease Market Segmentation: By Distribution Channel

3.10.1 Global Cystic Fibrosis Lung Disease Market, By Distribution Channel Overview

3.10.2 Global Cystic Fibrosis Lung Disease Market Size, By Hospital Pharmacies By Value, 2019H-2029F (USD Billion & CAGR)

3.10.3 Global Cystic Fibrosis Lung Disease Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

3.10.4 Global Cystic Fibrosis Lung Disease Market Size, By Online Channel, By Value, 2019H-2029F (USD Billion & CAGR)

4. Global Cystic Fibrosis Lung Disease Market, Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Cystic Fibrosis Lung Disease Market: Historic and Forecast (2019-2029)

5.1 Americas Cystic Fibrosis Lung Disease Market: Snapshot

5.2 Americas Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Billion & CAGR)

5.3 Americas Cystic Fibrosis Lung Disease Market: Key Factors

5.4 Americas Cystic Fibrosis Lung Disease Market : Segment Analysis

5.5 Americas Cystic Fibrosis Lung Disease Market Segmentation: By Drug Type

5.5.1 Americas Cystic Fibrosis Lung Disease Market, By Drug Type Overview

5.5.2 Americas Cystic Fibrosis Lung Disease Market Size, By CFTR modulators, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.3 Americas Cystic Fibrosis Lung Disease Market Size, By Bronchodilators, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.4 Americas Cystic Fibrosis Lung Disease Market Size, By Mucolytics, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.5 Americas Cystic Fibrosis Lung Disease Market Size, By Anti infectives, By Value, 2019H-2029F (USD Billion & CAGR)

5.6 Americas Cystic Fibrosis Lung Disease Market Segmentation: By Route of Administration

5.6.1 Americas Cystic Fibrosis Lung Disease Market, By Route of Administration Overview

5.6.2 Americas Cystic Fibrosis Lung Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)

5.6.3 Americas Cystic Fibrosis Lung Disease Market Size, By Inhalation, By Value, 2019H-2029F (USD Billion & CAGR)

5.6.4 Americas Cystic Fibrosis Lung Disease Market Size, By Intravenous, By Value, 2019H-2029F (USD Billion & CAGR)

5.7 Americas Cystic Fibrosis Lung Disease Market Segmentation: By Distribution Channel

5.7.1 Americas Cystic Fibrosis Lung Disease Market, By Distribution Channel Overview

5.7.2 Americas Cystic Fibrosis Lung Disease Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

5.7.3 Americas Cystic Fibrosis Lung Disease Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

5.7.4 Americas Cystic Fibrosis Lung Disease Market Size, By Online Channel, By Value, 2019H-2029F (USD Billion & CAGR)

5.8 Americas Cystic Fibrosis Lung Disease Market Segmentation : By Country

5.8.1 United States Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

5.8.1.1 United States Cystic Fibrosis Lung Disease Market, By Drug Type

5.8.1.2 United States Cystic Fibrosis Lung Disease Market, By Route of Administration

5.8.1.3 United States Cystic Fibrosis Lung Disease Market, By Distribution Channel

5.8.2 Canada Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

5.8.2.1 Canada Cystic Fibrosis Lung Disease Market, By Drug Type

5.8.2.2 Canada Cystic Fibrosis Lung Disease Market, By Route of Administration

5.8.2.3 Canada Cystic Fibrosis Lung Disease Market, By Distribution Channel

5.8.3 Rest of Americas Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

5.8.3.1 Rest of Americas Cystic Fibrosis Lung Disease Market, By Drug Type

5.8.3.2 Rest of Americas Cystic Fibrosis Lung Disease Market, By Route of Administration

5.8.3.3 Rest of Americas Cystic Fibrosis Lung Disease Market, By Distribution Channel

6. Europe Cystic Fibrosis Lung Disease Market: Historic and Forecast (2019-2029)

6.1 Europe Cystic Fibrosis Lung Disease Market: Snapshot

6.2 Europe Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Billion & CAGR)

6.3 Europe Cystic Fibrosis Lung Disease Market: Key Factors

6.4 Europe Cystic Fibrosis Lung Disease Market: Segment Analysis

6.5 Europe Cystic Fibrosis Lung Disease Market Segmentation: By Drug Type

6.5.1 Europe Cystic Fibrosis Lung Disease Market, By Drug Type Overview

6.5.2 Europe Cystic Fibrosis Lung Disease Market Size, By CFTR modulators, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.3 Europe Cystic Fibrosis Lung Disease Market Size, By Bronchodilators, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.4 Europe Cystic Fibrosis Lung Disease Market Size, By Mucolytics, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.5 Europe Cystic Fibrosis Lung Disease Market Size, By Anti infectives, By Value, 2019H-2029F (USD Billion & CAGR)

6.6 Europe Cystic Fibrosis Lung Disease Market Segmentation: By Route of Administration

6.6.1 Europe Cystic Fibrosis Lung Disease Market, By Route of Administration Overview

6.6.2 Europe Cystic Fibrosis Lung Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)

6.6.3 Europe Cystic Fibrosis Lung Disease Market Size, By Inhalation, By Value, 2019H-2029F (USD Billion & CAGR)

6.6.4 Europe Cystic Fibrosis Lung Disease Market Size, By Intravenous, By Value, 2019H-2029F (USD Billion & CAGR)

6.7 Europe Cystic Fibrosis Lung Disease Market Segmentation: By Distribution Channel

6.7.1 Europe Cystic Fibrosis Lung Disease Market, By Distribution Channel Overview

6.7.2 Europe Cystic Fibrosis Lung Disease Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

6.7.3 Europe Cystic Fibrosis Lung Disease Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

6.7.4 Europe Cystic Fibrosis Lung Disease Market Size, By Online Channel, By Value, 2019H-2029F (USD Billion & CAGR)

6.8 Europe Cystic Fibrosis Lung Disease Market Segmentation : By Country

6.8.1 Germany Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.1.1 Germany Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.1.2 Germany Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.1.3 Germany Cystic Fibrosis Lung Disease Market, By Distribution Channel

6.8.2 United Kingdom Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.2.1 United Kingdom Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.2.2 United Kingdom Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.2.3 United Kingdom Cystic Fibrosis Lung Disease Market, By Distribution Channel

6.8.3 France Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.3.1 France Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.3.2 France Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.3.3 France Cystic Fibrosis Lung Disease Market, By Distribution Channel

6.8.4 Italy Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.4.1 Italy Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.4.2 Italy Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.4.3 Italy Cystic Fibrosis Lung Disease Market, By Distribution Channel

6.8.5 Spain Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.5.1 Spain Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.5.2 Spain Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.5.3 Spain Cystic Fibrosis Lung Disease Market, By Distribution Channel

6.8.6 Rest of Europe Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

6.8.6.1 Rest of Europe Cystic Fibrosis Lung Disease Market, By Drug Type

6.8.6.2 Rest of Europe Cystic Fibrosis Lung Disease Market, By Route of Administration

6.8.6.3 Rest of Europe Cystic Fibrosis Lung Disease Market, By Distribution Channel

7. Asia-Pacific Cystic Fibrosis Lung Disease Market: Historic and Forecast (2019-2029)

7.1 Asia-Pacific Cystic Fibrosis Lung Disease Market: Snapshot

7.2 Asia-Pacific Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Billion & CAGR)

7.3 Asia-Pacific Cystic Fibrosis Lung Disease Market: Key Factors

7.4 Asia-Pacific Cystic Fibrosis Lung Disease Market: Segment Analysis

7.5 Asia-Pacific Cystic Fibrosis Lung Disease Market Segmentation: By Drug Type

7.5.1 Asia-Pacific Cystic Fibrosis Lung Disease Market, By Drug Type Overview

7.5.2 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By CFTR modulators, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.3 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Bronchodilators, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.4 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Mucolytics, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.5 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Anti infectives, By Value, 2019H-2029F (USD Billion & CAGR)

7.6 Asia-Pacific Cystic Fibrosis Lung Disease Market Segmentation: By Route of Administration

7.6.1 Asia-Pacific Cystic Fibrosis Lung Disease Market, By Route of Administration Overview

7.6.2 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)

7.6.3 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Inhalation, By Value, 2019H-2029F (USD Billion & CAGR)

7.6.4 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Intravenous, By Value, 2019H-2029F (USD Billion & CAGR)

7.7 Asia-Pacific Cystic Fibrosis Lung Disease Market Segmentation : By Distribution Channel

7.7.1 Asia-Pacific Cystic Fibrosis Lung Disease Market, By Distribution Channel Overview

7.7.2 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

7.7.3 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

7.7.4 Asia-Pacific Cystic Fibrosis Lung Disease Market Size, By Online Channel, By Value, 2019H-2029F (USD Billion & CAGR)

7.8 Asia-Pacific Cystic Fibrosis Lung Disease Market Segmentation : By Country

7.8.1 China Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

7.8.1.1 China Cystic Fibrosis Lung Disease Market, By Drug Type

7.8.1.2 China Cystic Fibrosis Lung Disease Market, By Route of Administration

7.8.1.3 China Cystic Fibrosis Lung Disease Market, By Distribution Channel

7.8.2 Australia Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

7.8.1.1 Australia Cystic Fibrosis Lung Disease Market, By Drug Type

7.8.1.2 Australia Cystic Fibrosis Lung Disease Market, By Route of Administration

7.8.1.3 Australia Cystic Fibrosis Lung Disease Market, By Distribution Channel

7.8.3 India Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

7.8.3.1 India Cystic Fibrosis Lung Disease Market, By Drug Type

7.8.3.2 India Cystic Fibrosis Lung Disease Market, By Route of Administration

7.8.3.3 India Cystic Fibrosis Lung Disease Market, By Distribution Channel

7.8.5 Rest of Asia-Pacific Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Million & CAGR)

7.8.5.1 Rest of Asia-Pacific Cystic Fibrosis Lung Disease Market, By Drug Type

7.8.5.2 Rest of Asia-Pacific Cystic Fibrosis Lung Disease Market, By Route of Administration

7.8.5.3 Rest of Asia-Pacific Cystic Fibrosis Lung Disease Market, By Distribution Channel

8. Middle-East & Africa Cystic Fibrosis Lung Disease Market: Historic and Forecast (2019-2029)

8.1 Middle-East & Africa Cystic Fibrosis Lung Disease Market: Snapshot

8.2 Middle-East & Africa Cystic Fibrosis Lung Disease Market: Market Size and CAGR, 2019H-2029F (USD Billion & CAGR)

8.3 Middle-East & Africa Cystic Fibrosis Lung Disease Market: Key Factors

8.4 Middle-East & Africa Cystic Fibrosis Lung Disease Market: Segment Analysis

8.5 Middle-East & Africa Cystic Fibrosis Lung Disease Market Segmentation: By Drug Type

8.5.1 Middle-East & Africa Cystic Fibrosis Lung Disease Market, By Drug Type Overview

8.5.2 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By CFTR modulators, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.3 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Bronchodilators, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.4 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Mucolytics, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.5 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Anti-infectives, By Value, 2019H-2029F (USD Billion & CAGR)

8.6 Middle-East & Africa Cystic Fibrosis Lung Disease Market Segmentation: By Route of Administration

8.6.1 Middle-East & Africa Cystic Fibrosis Lung Disease Market, By Route of Administration Overview

8.6.2 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.3 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Inhalation, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.4 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Intravenous, By Value, 2019H-2029F (USD Billion & CAGR)

8.6 Middle-East & Africa Cystic Fibrosis Lung Disease Market Segmentation: By Distribution Channel

8.6.1 Middle-East & Africa Cystic Fibrosis Lung Disease Market, By Distribution Channel: Overview

8.6.2 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.3 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.4 Middle-East & Africa Cystic Fibrosis Lung Disease Market Size, By Online Channel, By Value, 2019H-2029F (USD Billion & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global Cystic Fibrosis Lung Disease Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Porter’s Five Forces Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of Cystic Fibrosis Lung Disease Market

11.4 Company Profiles

11.4.1 Vertex Pharmaceuticals

11.4.2 Gsk plc

11.4.3 Novartis AG

11.4.4 Roche Holding AG

11.4.5 Bayer AG

11.4.6 Gilead Sciences

11.4.7 Chiesi Farmaceutici S.p.A.

11.4.8 Enterprise Therapeutics

11.4.9 Laurent Pharma

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Cystic Fibrosis Lung Disease Market (2024 Edition)” which provides a complete analysis of the global Cystic Fibrosis Lung Disease industry in terms of market segmentation by Drug Type (CFTR Modulators, Bronchodilators, Mucolytics, Anti-infectives) and By Route of Administration (Oral, Inhalation, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Australia, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution. During the forecast period, 2024-2029, the Global Cystic Fibrosis Lung Disease market is expected to grow at a CAGR of 25.7%. The Global Cystic Fibrosis Lung Disease Market is expected to generate USD 46.87 Billion by the end of 2029, up from USD 10.75 Billion in 2022.

The cystic fibrosis lung disease market is propelled by continuous advancements in therapeutic interventions. Pharmaceutical companies are investing heavily in research and development to bring innovative treatments to the forefront. Moreover, the emergence of novel drugs and therapies, such as gene therapies and CFTR modulators, has significantly improved the treatment landscape for cystic fibrosis patients. These advancements not only enhance patient outcomes but also contribute to the overall growth of the market.

Additionally, the rising awareness of cystic fibrosis among healthcare professionals and patients is a significant driver for market growth. Improved diagnostic capabilities and increased disease education efforts contribute to early detection and intervention which is contributing to the market growth.

Scope of the Report

• The report analyses the Cystic Fibrosis Lung Disease Market by Value (USD Billion).

• The report presents the analysis of the Cystic Fibrosis Lung Disease Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Cystic Fibrosis Lung Disease Market by Drug Type (CFTR Modulators, Bronchodilators, Mucolytics).

• The report analyses the Cystic Fibrosis Lung Disease Market By Route of Administration (Oral, Inhalation, Intravenous)

• The report analyses the Cystic Fibrosis Lung Disease Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, Drug Type, Route of Administration and Distribution Channels.

• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.

• The report also analyses the pipeline framework of the Dugs for the Cystic Fibrosis Lung Disease

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Vertex Pharmaceuticals, Gsk plc, Novartis AG, Roche Holding AG, Bayer AG, Gilead Sciences, Chiesi Farmaceutici S.p.A., Enterprise Therapeutics, and Laurent Pharma.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

嚢胞性線維症（CF）肺疾患の世界市場（2024年版）：薬剤タイプ別（CFTR調節薬、気管支拡張薬、粘液溶解薬、抗感染薬）、投与経路別、流通経路別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?